Collagenase clostridium histolyticum(University of Alberta)(Collagenase clostridium histolyticum(University of Alberta))

概要

基本信息

药物类型

酶

别名-

靶点

Collagen

作用方式-

作用机制

胶原酶替代物

治疗领域

肿瘤神经系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

掌腱膜挛缩症

原研机构

University of Alberta

在研机构-

非在研机构

University of Alberta

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Collagenase clostridium histolyticum(University of Alberta) 相关的临床试验

NCT01776892

/ Withdrawn临床3期IIT

Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease

Dupuytren's disease results in deformity of the hand and this can lead to trouble with daily activities. Treatment traditionally involves cutting out diseased tissue, however this can cause damage to important structures in the hand and results in large scars.
Needle aponeurotomy and collagenase injections are newer treatments that are thought to be safer. These treatments allow quicker return to function. One drawback is that Dupuytren's deformity may return more quickly than when all diseased tissue is surgically cut out.
This research study is designed to compare the effectiveness of needle aponeurotomy and collagenase injection for Dupuytren's disease. This study will determine which procedure gives the best results- either needle aponeurotomy, collagenase injection, or both procedures in combination. Participants will be evaluated to see how they do in the long term.

开始日期2013-05-01

申办/合作机构

University of Alberta

100 项与 Collagenase clostridium histolyticum(University of Alberta) 相关的临床结果

登录后查看更多信息

100 项与 Collagenase clostridium histolyticum(University of Alberta) 相关的转化医学

登录后查看更多信息

100 项与 Collagenase clostridium histolyticum(University of Alberta) 相关的专利（医药）

登录后查看更多信息

27

项与 Collagenase clostridium histolyticum(University of Alberta) 相关的文献（医药）

2026-01-07·Journal of Sexual Medicine

The impact of the “bent carrot”: Google search trends on Peyronie’s disease increased following the introduction of collagenase clostridium histolyticum advertisement campaign

Article

作者: Rotker, Katherine ; Choksi, Ankur U ; Honig, Stanton C ; Cahill, Ellen M

2025-05-10·Journal of Sexual Medicine

Are patients undergoing intralesional collagenase Clostridium histolyticum injection therapy for Peyronie’s disease compliant? A 7-year analysis from a tertiary care men’s health center

Article

作者: Abou Chawareb, Elia ; Nakamura, Hana ; Yafi, Faysal A ; Lumbiganon, Supanut ; Hammad, Muhammed A M

Abstract:

Background:

Peyronie’s disease (PD) involves the formation of fibrous scar tissue in the penis, causing pain, deformity, and significant psychological and sexual distress. Intralesional injection of collagenase Clostridium histolyticum (CCH) has emerged as a promising non-surgical treatment, though patients may experience complications and require multiple clinic visits.

Aim:

This study aims to evaluate patient compliance with CCH therapy, compare outcomes between compliant and non-compliant groups, and identify reasons for non-compliance.

Methods:

This IRB-approved retrospective study analyzed patients with PD between 2017 and 2023. Patients were evaluated by a fellowship-trained andrologist. Patients who elected to have intralesional CCH were initially offered four cycles of treatment, with compliance defined as completing at least four cycles or achieving satisfactory results with fewer cycles.

Outcomes:

Data on demographics, disease characteristics, treatment modalities, compliance, and outcomes were extracted from electronic medical records, and causes of non-compliance were identified. Outcomes and complications were compared between compliant and non-compliant groups.

Results:

Two hundred and ninety-two PD patients elected to have an intralesional injection of collagenase CCH. Among these, 51.4% completed four treatment cycles, 14.7% received more than four cycles, and 33.9% received fewer than four cycles. The overall compliance rate for injection therapy, including those satisfied with fewer cycles, was 70.89%. Mean pre-treatment curvature for 292 patients was 46.77 ± 14.26 degrees. Compliant patients showed a greater percent of curvature reduction (median 44.44 (IQR 34.17) vs 33.33 (IQR 44.17), P = .034) and less post-treatment curvature in degree (median 25.00 (IQR 17.02) vs 30.00 (IQR 23.75), P = .032) compared to non-compliant patients. Common reasons for incomplete treatment included adverse effects (15.1%), early satisfaction with results (14.1%), and unknown factors (45.4%).

Clinical Implications:

Compliance with CCH therapy for PD significantly impacts treatment outcomes. Healthcare providers should address factors contributing to non-compliance. Qualitative studies are recommended to gain deeper insights into non-compliant patients.

Strengths and Limitations:

This study analyzed compliance in a large cohort of PD patients and compared outcomes between compliant and non-compliant groups. However, missing data in the non-compliant group and the bias between compliant and non-compliant patients in this retrospective study are major notable limitations.

Conclusion:

Overall compliance rate for CCH injection therapy was 70.89%. Greater curvature reduction was demonstrated in compliant patients. Common reasons for incomplete treatment included adverse effects (15.1%), early satisfaction with results (14.1%), and unknown factors (45.4%). However, missing data and bias from retrospective design are major limitations.

2025-01-01·Case reports in urology

Late-Onset Penile Fracture After Collagenase Clostridium histolyticum Treatment for Peyronie's Disease in a 70-Year-Old Patient.

Article

作者: Masih, Sonia E ; Schuster, Timothy G ; Wainstein, Matthew D

Collagenase Clostridium histolyticum (CCH) injections are the gold standard for nonsurgical management of Peyronie's disease. While generally well tolerated, penis fracture is a known complication. Cases typically occur during intercourse in the weeks following treatment. Because of this, patients are advised to abstain from sexual activity for 4 weeks postinjection. Here, we present a case of corporal rupture occurring 32 days after treatment. This is only the third reported case occurring 30 days after injection. While the risk of penis fracture likely decreases with time, these cases illustrate that the risk may extend beyond 4 weeks.

100 项与 Collagenase clostridium histolyticum(University of Alberta) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
掌腱膜挛缩症	临床3期	加拿大	University of Alberta	2013-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EULAR2011	N/A	掌腱膜挛缩症	1,082	CCH treatment on the Operated hand	網壓遞齋積鏇廠範鹹蓋(製襯醖選鏇積願範範積) = 糧淵鑰範衊製網鑰觸積鬱獵壓積蓋鹽膚壓鏇積 (觸廠繭鑰鏇積繭艱願願, 2.8%) 更多	-	2011-05-25
				CCH treatment on the Non-operated hand	網壓遞齋積鏇廠範鹹蓋(製襯醖選鏇積願範範積) = 構獵淵構鏇鑰憲鹹鏇鬱鬱獵壓積蓋鹽膚壓鏇積 (觸廠繭鑰鏇積繭艱願願, 2.0%) 更多